Navigation Links
The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
Date:11/6/2007

Over 300 implants reported in the intended patient population for company's

minimally invasive knee implant.

MINNEAPOLIS, Nov. 6 /PRNewswire/-- Advanced Bio-Surfaces, Inc., (ABS) an orthopedic implant developer and manufacturer, announced today the OrthoGlide Medial Knee Implant has been implanted in more than 300 patients in the USA. The OrthoGlide implant is a minimally invasive device intended to relieve pain caused by moderate osteoarthritis of the knee.

"The interest from surgeons and patients for a minimally invasive alternative to the current knee replacement options on the market continues to expand," said Dr. Jeff Felt, Chairman of Advanced Bio-Surfaces. "We have increased the number of training sites in the United States in an effort to accommodate the number of interested surgeons. As the surgeon community learns more about the product and its minimal surgical approach, they understand the need for the OrthoGlide implant as a viable option for some patients. The growth is inspired by surgeons who want to be trained on a procedure that can be positioned as an alternative to total knee replacement."

In addition to training and supporting the orthopedic surgeon community interested in the OrthoGlide implant, ABS is also involved in a clinical study. This week, during the American College of Rheumatology's annual meeting in Boston, MA, William Arnold, M.D. will present data from the study that supports the OrthoGlide's clinical effectiveness. The presentation will be held in Room 153 of the Boston Convention and Exhibit Center at 5:30 p.m. on Saturday, November 10th.

About Advanced Bio-Surfaces, Inc.

ABS is a privately held company dedicated to the development of innovative joint restoration products. The company's first product, the OrthoGlide Medial Knee Implant, is intended for the treatment of patients with moderate osteoarthritis of the medial compartment. The company received 510(k) clearance to market from the U.S. Food and Drug Administration (FDA) and CE mark notification from its Notified Body, in February 2006. For additional information contact ABS at 952.912.5400 or visit the website at http://www.advbiosurf.com.


'/>"/>
SOURCE Advanced Bio-Surfaces, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
2. Adult Smoking Rate Continues Downward Trend
3. Gilbert Hospital Continues Cutting Edge Treatments
4. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
9. Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
10. Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
11. Facet Solutions Enjoys Continued Clinical Success With the Anatomic Facet Replacement System (AFRS(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Maxor National Pharmacy Services, LLC ... it has named Leah Bailey as General ... of the company. With more than 13 ... 8 years focused on health care, Bailey joins the ... at Prime, Bailey advised the PBM, Specialty, and Mail ...
(Date:3/29/2017)... WASHINGTON , March 29, 2017  The Pharmaceutical ... regarding a new PhRMA report on patient out-of-pocket spending: ... for Medicare and Medicaid Services (CMS), the average amount ... be 13% of drug spending in 2016, down from ... is a pricing problem, not a coverage problem. Health ...
(Date:3/29/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The ablation device global market is expected to grow ... Ablation is the minimally invasive therapeutic tissue excision ... diseased tissue removal, to the removal of abnormally conducting cardiac tissue ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an important webinar — ... 1:00 PM ET. A recording of the webinar will also be made available following ... health and hospice companies are still popular targets for healthcare investors. This highly fragmented ...
(Date:3/29/2017)... ... 2017 , ... Immunotherapy has emerged as one of the most promising options ... be the next revolution in our fight against this complex disease. One of the ... checkpoint inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... Hills of Pittsburgh now have easier access to the robotic-assisted total-hip and ... Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently ...
(Date:3/29/2017)... ... , ... The Wharton School of the University of Pennsylvania is pleased to ... $10 million gift to establish the Ken Moelis and Julie Taffet Moelis Advance ... Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions ...
Breaking Medicine News(10 mins):